Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans

The effect of pretreatment with paroxetine on cell-mediated immune response and release of cytokines after the administration of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) was investigated in a double-blind, randomized, crossover, controlled clinical trial in which 12 healthy male recreational users of MDMA participated. Subjects received 20 mg/day paroxetine (or placebo) for the 3 days before MDMA challenge (100 mg). Acute MDMA administration produced a time-dependent decrease in CD4 T-helper cells, a decrease in the functional responsiveness of lymphocytes to mitogenic stimulation, a simultaneous increase in natural killer (NK) cells as well as cortisol and prolactin stimulation kinetics. A high increase in the release of anti-inflammatory cytokines (transforming growth factor-β and interleukin-10) with a simultaneous decrease of anti-inflammatory response (interleukin-2) was also observed. Pretreatment with paroxetine partially reduced MDMA effects on CD4 T and NK cells, whereas totally inhibiting the suppression of the immune response to mitogens and alterations in cytokines release. MDMA-induced alterations in the immune system as well as antagonistic effects mediated by paroxetine show a trend toward baseline levels at 24 h. These findings suggest that acute effects of MDMA on immune system are mainly mediated by its interaction with the serotonin transporter and subsequent serotonin release with a possible participation of other neuroendocrine regulatory systems.

[1]  F. Fonnum,et al.  Short- and long-term effects of MDMA (“ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo , 2003, Neurochemistry International.

[2]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[3]  R. de la Torre,et al.  Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies. , 2003, Rapid communications in mass spectrometry : RCM.

[4]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[5]  M. Farré,et al.  Cell‐Mediated Immune Response in MDMA Users After Repeated Dose Administration , 2002 .

[6]  M. Forsling,et al.  Action of MDMA (Ecstasy) and Its Metabolites on Arginine Vasopressin Release , 2002, Annals of the New York Academy of Sciences.

[7]  M. Geyer,et al.  Acute Psychological and Neurophysiological Effects of MDMA in Humans , 2002, Journal of psychoactive drugs.

[8]  D. Grandy,et al.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. , 2001, Molecular pharmacology.

[9]  F. Vollenweider,et al.  Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies , 2001, Human psychopharmacology.

[10]  R. de la Torre,et al.  Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans. , 2001, Life sciences.

[11]  M. Forsling,et al.  Arginine vasopressin release in response to the administration of 3,4‐methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? , 2001, The Journal of pharmacy and pharmacology.

[12]  Kathryn A. Cunningham,et al.  College on Problems of Drug Dependence , 2001 .

[13]  M. Farré,et al.  Pharmacology of MDMA in Humans , 2000, Annals of the New York Academy of Sciences.

[14]  M. Farré,et al.  Immunomodulating Activity of MDMA , 2000, Annals of the New York Academy of Sciences.

[15]  J. Kelly,et al.  Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challenge , 2000 .

[16]  R. de la Torre,et al.  Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. , 2000, Journal of clinical psychopharmacology.

[17]  F. Vollenweider,et al.  The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers , 2000, Journal of psychopharmacology.

[18]  S. Basu,et al.  Dopamine, a neurotransmitter, influences the immune system , 2000, Journal of Neuroimmunology.

[19]  R. de la Torre,et al.  Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. , 1999, Life sciences.

[20]  I. Krasnov,et al.  Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system , 1999, Journal of Neuroimmunology.

[21]  F. Vollenweider,et al.  Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.

[22]  R. de la Torre,et al.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  M. Delaforge,et al.  Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. , 1999, Environmental toxicology and pharmacology.

[24]  K. Lesch,et al.  Role of Serotonin in the Immune System and in Neuroimmune Interactions , 1998, Brain, Behavior, and Immunity.

[25]  H. Sugihara,et al.  Brain vasopressin is involved in stress-induced suppression of immune function in the rat , 1998, Brain Research.

[26]  D. Marazziti,et al.  Presence and Characterization of the Serotonin Transporter in Human Resting Lymphocytes , 1998, Neuropsychopharmacology.

[27]  M. Forsling,et al.  Low-dose MDMA (“ecstasy”) induces vasopressin secretion , 1998, The Lancet.

[28]  T. Wilckens,et al.  Glucocorticoids and immune function: unknown dimensions and new frontiers. , 1997, Immunology today.

[29]  L. Matera,et al.  Endocrine, paracrine and autocrine actions of prolactin on immune cells. , 1996, Life sciences.

[30]  L. Seiden,et al.  Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.

[31]  G. Gudelsky,et al.  Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions , 1996, Journal of neurochemistry.

[32]  R. Poland,et al.  Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations , 1995, Behavioural Brain Research.

[33]  W. Sosroseno,et al.  The immunoregulatory roles of transforming growth factor beta. , 1995, British journal of biomedical science.

[34]  R. Pacifici,et al.  Cytokine Production in Blood Mononuclear Cells from Epileptic Patients , 1995, Epilepsia.

[35]  E. Azmitia,et al.  The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.

[36]  S. Peroutka,et al.  5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. , 1990, European journal of pharmacology.

[37]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[38]  Eliseeva Ls,et al.  Specific binding of serotonin by blood leukocytes and peritoneal cells in the mouse , 1982 .

[39]  M. Farré,et al.  Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans , 2005, Clinical pharmacokinetics.

[40]  R. de la Torre,et al.  3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. , 2002, The Journal of pharmacology and experimental therapeutics.

[41]  M. Farré,et al.  Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[43]  M. Irwin,et al.  Modulation of immune cell function by the autonomic nervous system. , 1997, Pharmacology & therapeutics.

[44]  T. Mosmann.  Properties and functions of interleukin-10. , 1994, Advances in immunology.

[45]  D. Henderson,et al.  Immunological studies on paroxetine, a novel anti-depressant drug. , 1988, International journal of immunopharmacology.